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Abstract
Background: RNA interference (RNAi) was originally identified as a biological process in which
short double-stranded RNA (dsRNA) suppress the expression of genes complimentary to the
dsRNA. This cellular intrinsic gene silencing mechanism has subsequently been developed as a
useful tool for studies of gene function. A major strategy for producing small interfering RNA
(siRNA) in cultured cells involves the use of siRNA expression vectors in which a RNA polymerase
III (Pol III) promoter and transcription stop signal are designed to constitute a functional siRNA
expression cassette for production of siRNA. However, most of the available vectors contain only
one siRNA expression cassette.
Results: In order to maximize the efficiency and versatility of the vector-based siRNA approach,
we have developed vectors containing multiple (up to six) tandem siRNA expression cassettes.
Moreover, we demonstrated that these vectors can be used not only to produce different siRNA
to simultaneously suppress the expression of multiple genes but also to maximize the silencing of
a singe gene.
Conclusion: The vectors containing multiple siRNA expression cassettes can serve as useful tools
for maximizing the efficiency of gene silencing.
Background
RNAi is a newly identified biological process in which spe-
cific sequence of short dsRNA (~22 bp) knock down the
expression of genes complimentary to the dsRNA. RNAi
was initially discovered in plants, worms and fruit flies as
an important biological mechanism controlling gene
expression and development [1]. It was later recognized
that short dsRNA complementary to particular messenger
RNA (mRNA) can specifically decrease the levels of the
mRNA through the RNAi pathway in mammalian systems
as well [2]. In vivo, siRNA are generated from long precur-
sor molecules by a specific RNase III-like endonuclease
called Dicer [3]. The siRNA is subsequently incorporated
into the RNA induced silencing complex (RISC), a pro-
tein/RNA complex. The siRNA allows specific recognition
of the mRNA target and the endonuclease activity of the
RISC cleaves and destroys mRNA, resulting in decreased
levels of the mRNA [3].
Moreover, RNAi, a cellular intrinsic gene silencing mech-
anism, has been developed to knock down gene expres-
sion in a variety of transformed and primary mammalian
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cells [4,5]. As such, the newly emerged siRNA technology
represents a valuable genetic tool for functional genomics
and cell signaling pathway analysis in the post-genome
sequence era [6]. Currently, there are two major strategies
for getting siRNA into mammalian cells to suppress the
expression of target genes. The first strategy involves in
vitro preparation of siRNA and subsequent delivery of the
in vitro prepared siRNAs into cells by means of transient
transfection [4]. siRNA are often prepared in vitro by
chemical synthesis, in vitro transcription or digestion of
long dsRNA by RNase III-like endonucleases such as
Dicer.
The second strategy involves the use of siRNA expression
vectors and is thus regarded as vector-based siRNA
approach [7,8]. siRNA expression vectors are primarily
plasmids or viral vectors designed for producing siRNA
within cultured mammalian cells after the vectors are
delivered into the cells. A typical siRNA expression vector
contains a functional siRNA expression unit (also referred
to as siRNA expression cassette). A siRNA expression cas-
sette requires Pol III promoter such as U6 promoter (the
promoter for U6 snRNA which is involved in transcript
splicing) and H1 promoter (the promoter for H1 RNA
which is a component of RNase P) [9]. In addition, two
unique restriction sites are created downstream of the pro-
moter for insertion of a small DNA insert encoding a short
hairpin RNA targeting the gene of interest. A transcription
stop signal for Pol III (namely, TTTTT) is included at the
3' end of the DNA insert [8]. Once the insert-containing
vectors are delivered into mammalian cells, they express
short hairpin RNA. The short hairpin RNA are then proc-
essed by Dicer into ~22 nt siRNA, which activate the RISC
complex to cleave the mRNA target and thus inactivate the
gene function [8].
Although the vector-based siRNA approach is widely used,
currently most vectors contain only one single siRNA
expression cassette. In order to maximize the efficiency
and versatility of the vector-based siRNA approach, using
an efficient cloning strategy we have developed a series of
siRNA expression vectors containing multiple tandem
siRNA cassettes (up to six). More importantly, we have
also carried out proof-of-concept experiments to demon-
strate that the tandem siRNA cassettes are functional and
capable of producing different siRNA. As a result, these
vectors can be used to produce different siRNA to simulta-
neously knock down the expression of multiple genes.
Moreover, these vectors can also be used to maximize the
silencing of a single gene by producing different siRNA
targeting the different regions of the gene or producing
multiple copies of siRNA targeting a single region of the
gene.
Results
Development of vectors containing multiple siRNA 
expression cassettes
To develop vectors containing multiple siRNA expression
cassettes, we used the cloning vector pBluescript II SK+
(SK+) from STRATAGENE (La Jolla, CA) and followed the
cloning strategy detailed in Fig. 1a and additional files
(see Additional file 1). SK+ was double digested with Sac
I and Kpn I to remove the multiple cloning sites (MCS). A
pair of oligonucleotides (P1-A and P1-B) were synthesized
and then annealed to form a short DNA duplex (~80-bp).
This DNA duplex contains numerous restriction sites
required for subsequent cloning steps. Importantly, the
DNA duplex starts with a cohesive end (3'-TCGA T-5')
which can recombine with the Sac I cohesive end (5'-G
AGCT-3). However, once recombined, they give rise to a
sequence (5'-GAGCTA-3') which is no longer a Sac I
restriction site. Similarly, the duplex DNA ends with a
cohesive end which can recombine with the Kpn I cohe-
sive end. But the resulting sequence is no longer a Kpn I
site. Consequently, the insertion of the DNA duplex into
the cut SK+ gave rise to Vector 1, which contains Not I,
Xba I, Sal I, Acc I, Sac I, a block, Eco RI and Nco I (Fig. 1a).
A mouse U6 promoter (mU6) was amplified by PCR using
mouse genomic DNA and cloned into SK+ between Spe I
and Xho I to prepare SK-mU6. mU6 was cut out from SK-
mU6 with Spe I and Xho I and cloned into Vector 1
between Xba I and Sal I (Fig. 1a). Notably, although the
cohesive ends generated by Xba I and Spe I are compati-
ble, once religated together, they will give rise to a
sequence which is no longer recognized by neither Xba I
nor Spe I. Similarly, the cohesive ends generated by Sal I
and Xho I are compatible, but religation of the ends result
in a sequence which is no longer recognized by neither Sal
I nor Xho I. This cloning strategy is important since it
destroys the Xba I and Sal I once the mU6 is cloned, thus
allowing the subsequent insertion of additional mU6 pro-
moters to the vector to generate multiple siRNA expres-
sion cassettes. The insertion of mU6 into Vector 1 resulted
in a vector containing one siRNA expression cassette, p1-
siRNA (Fig. 1a).
To develop a vector containing two siRNA expression cas-
settes, a pair of oligonucleotides (P2-A and P2-B) was
used (Fig. 1a). This short DNA duplex also contains
numerous restriction sites including Xba I and Sal I for
subsequent addition of mU6 and Kpn I and Pst I for future
cloning of DNA insert encoding siRNA. Moreover, the
DNA duplex starts with the Eco RI cohesive site and ends
with the Nco I cohesive site for insertion into p1-siRNA to
generate Vector 2. Then, mU6 was cloned into Vector 2 to
produce p2-siRNA. Using a similar cloning strategy, we
also prepared four additional vectors: p3-siRNA, p4-
siRNA, p5-siRNA and p6-siRNA, which contain 3, 4, 5 and
6 siRNA expression cassettes, respectively (see AdditionalBMC Biotechnology 2006, 6:50 http://www.biomedcentral.com/1472-6750/6/50
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file 1). Each cassette consists of a mouse U6 promoter, a
pair of cloning sites and a block (Fig. 1b). When oligonu-
cleotides designed for producing siRNA are cloned
between the cloning sites in each cassette, mouse U6 pro-
moter will drive the production of siRNA. The blocks are
used to minimize potential cross-interference among
these cassettes.
The vectors with multiple siRNA expression cassettes can 
be used to simultaneously inhibit the expression of 
different genes
To determine whether these vectors can be used to simul-
taneously inhibit the expression of multiple genes, we
tested the ability of p3-siRNA to produce three different
siRNA to target three different genes. In our laboratory, we
are primarily working with mouse bone marrow macro-
phages (BMMs) and BMMs express various tumor necrosis
factor-associated factors (TRAF) including TRAF1, 2 and 6
[10]. To this end, we obtained effective siRNA sequences
targeting mRNA encoding TRAF1, 2 and 6 by testing vari-
ous putative sequences identified using the siRNA target
finder provided by Ambion (Austin, TX) (data not
shown). We synthesized three pairs of oligonucleotides
and annealed them to form three DNA duplexes: Si1, Si2
and Si6 which encode siRNA targeting TRAF1, TRAF2 and
TRAF6, respectively (see Additional file 2). Si1, Si2 and Si6
were cloned into p3-siRNA to construct TR126 (Fig. 2a).
In addition, we also prepared control constructs TR1, TR2
and TR6, each containing a single siRNA expression cas-
sette that express siRNA targeting TRAF1, TRAF2 or TRAF6,
respectively (Fig. 2a).
Since BMMs are not transfectable, we have been using ret-
rovirus technology to transduce genes into primary BMMs
in our laboratory [11,12]. Thus, we subcloned TR1, TR2,
TR6 or TR126 into a retroviral vector called pMX-siRNA
vector between Not I and Nco I (Fig. 2b). The virus super-
natants prepared using the retroviral vectors were used to
infect BMMs and the positively infected cells were selected
with puromycin. The expression levels of the three TRAF
proteins in BMMs infected with the virus encoding TR1,
TR2, TR6 or TR126 were determined by Western analysis.
The data indicated that TR1, TR2 and TR6 significantly
inhibited the expression of TRAFs 1, 2 and 6, respectively
(lane 1 in Fig. 2c,2d and 2e). Importantly, TR126 was also
able to significantly suppress the expression of TRAF1,
TRAF2 and TRAF6 (lane 2 in Fig. 2c,2d and 2e), indicating
that the three siRNA cassettes in p3-siRNA vector are all
functional and that p3-siRNA vector is able to simultane-
ously produce 3 different siRNA to knock down the
expression of three different genes. The assays shown in
Fig. 2 were performed with p3-siRNA and served as proof-
of-concept experiments. Based on these assays, we think
that other vectors such as p2-siRNA, p4-siRNA, p5-siRNA
and p6-siRNA shown in Fig. 1b should also be able to pro-
duce different siRNA to inhibit the expression of different
number of genes.
The vectors with multiple siRNA expression cassettes can 
also be used to maximize the efficiency of gene silencing
We next determined whether these vectors can be used to
maximize the efficiency of gene silencing by producing
siRNA targeting different regions of a gene or by produc-
Cloning strategy for constructing vectors containing multiple  siRNA expression cassettes Figure 1
Cloning strategy for constructing vectors containing 
multiple siRNA expression cassettes. a) Detailed proce-
dures for constructing the vectors containing a single siRNA 
expression cassette (p1-siRNA) or two siRNA cassettes (p2-
siRNA). SK+: pBluescript II SK+; MCS: multiple cloning sites; 
mU6: mouse U6 promoter. The restriction sites in blue high-
light the cloning sites for insertion of DNA duplex encoding 
siRNA. b) Schematic diagram showing the six vectors con-
taining multiple siRNA expression cassettes: p1-siRNA, p2-
siRNA, p3-siRNA, p4-siRNA, p5-siRNA and p6-siRNA. Each 
cassette contains a mouse U6 promoter (mU6), a pair of 
cloning sites for insertion of DNA duplex encoding siRNA 
(highlighted in blue) and a block which is included to prevent 
potential cross-interference among these cassettes. Detailed 
procedures for constructing p3-siRNA, p4-siRNA, p5-siRNA 
and p6-siRNA are provided (see Additional file 1).BMC Biotechnology 2006, 6:50 http://www.biomedcentral.com/1472-6750/6/50
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ing more copies of a single siRNA targeting the same
region of a gene. To this end, we used Si6 which was able
to suppress TRAF6 expression (Fig. 2e). In addition, we
identified another effective siRNA sequence (Si6A) target-
ing a different region of TRAF6 mRNA (Fig. 3a) (data not
shown). We used these siRNA sequences to prepare 4 vec-
tors: Vec2, Vec6, Vec26 and Vec66. Vec2 and Vec6 were
constructed by cloning a DNA insert encoding Si6A or Si6
into p1-siRNA. Vec2 and Vec6 were used as controls.
Vec26 was prepared by ligating both the DNA insert
encoding Si6A and the one encoding Si6 into p2-siRNA.
The DNA insert encoding Si6 was cloned into both siRNA
expression cassettes in p2-siRNA to give rise to Vec66 (Fig.
3a).
We then subcloned Vec2, Vec6, Vec26 and Vec66 into
pMX-siRNA vector (Fig. 2b) and virus supernatants pre-
pared using the resulting retroviral vectors were used to
infect BMMs. The expression levels of TRAF6 were deter-
mined by Western analysis. As shown in Fig. 3b, the pro-
duction of Si6 by two siRNA cassettes (Vec66) led to a
more profound inhibitory effect on TRAF6 expression
than single siRNA cassette (Fig. 3b), indicating that the
vectors containing multiple siRNA cassettes may also be
able to maximize the efficiency of gene silencing by
expressing more copies of siRNA targeting the same region
of a gene.
Moreover, the simultaneous production of both Si6A and
Si6 by Vec26 exerted higher inhibitory effect on the TRAF6
expression (lane 5, Fig. 3c) than the single siRNA (lanes 3
and 4), supporting that the vectors with multiple siRNA
expression cassettes have potential to increase the effi-
ciency of gene silencing by expressing different siRNA tar-
geting distinct regions of a gene. Notably, in the previous
assays, we used uninfected BMMs as controls. Given the
consideration that retroviral infection may cause non-spe-
cific inhibitory effect, we included additional controls
(Vec2C and Vec6C) in Fig. 3c. Vec2C contains the scram-
bled Si6A sequence while Vec6C has the scrambled Si6
sequence. Although these controls showed that retroviral
infection indeed caused non-specific inhibitory effect, the
data do not affect our conclusion that the vectors with
multiple siRNA expression cassettes have potential to
increase the efficiency of gene silencing by expressing dif-
ferent siRNA targeting distinct regions of a gene. Impor-
tantly, the same notion applies to other assays in our
current study.
Discussion
Since the development of siRNA as a genetic tool for gene
function studies, two major strategies have been used for
getting sufficient amount of siRNA into cultured mamma-
lian cells to knock down gene expression. The first strategy
involves direct delivery of the in vitro prepared siRNA into
mammalian cells by means of transient transfection [4,5].
The major advantage of this strategy is that a large amount
of siRNA may be prepared in vitro and then delivered by
transient transfection into cells to induce a high magni-
tude of gene silencing if the cells can be easily and effi-
ciently transfected. However, this strategy inherits two
disadvantages: first, the gene silencing using this strategy
is transient. Secondly, since some mammalian cells, espe-
cially primary cells, can not be efficiently transfected by
the current transfection methods, the use of this strategy is
largely limited to transfectable cells.
The second strategy is to use siRNA expression vectors [7-
9]. The vector-based siRNA approach has several advan-
tages: first, a selection marker (i.e. an antibiotic resistance
gene) may be included in the vector for subsequent selec-
tion of positively transfected cells to maximize the effect
of the gene silencing. Secondly, stable transfectants may
be generated using the vector-based siRNA approach to
achieve long-term gene silencing. Alternatively, siRNA
expression cassettes can be incorporated into viral vectors
(retrovirus or adenovirus) to express siRNA in non-trans-
fectable cells, especially primary cells. However, despite its
increasing popularity, the vector-based approach has not
been fully developed to harness its ultimate potential as a
p3-siRNA is able to produce three different siRNAs to simul- taneously suppress the expression of three different genes Figure 2
p3-siRNA is able to produce three different siRNAs 
to simultaneously suppress the expression of three 
different genes. a) Construction of TR126 and three con-
trol vectors: TR1, TR2 and TR3. Sequence of Si1, Si2 and Si6 
are shown in additional files (Additional file 2). b) Schematic 
structure of retroviral vector pMX-siRNA. c) – e) Western 
analysis showing that TR126 is able to suppress the expres-
sion of TRAF1 c); TRAF2 d) and TRAF6 e). C: uninfected 
BMMs controls. Actin was probed as loading control. The 
expression levels of TRAF proteins were normalized to that 
of actin. These assays were independently repeated three 
times and a representative data is shown.BMC Biotechnology 2006, 6:50 http://www.biomedcentral.com/1472-6750/6/50
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tool for gene silencing, primarily because most available
vectors utilize only one siRNA expression cassette.
Here we report the development and validation of a series
of vectors containing multiple siRNA expression cassettes
for maximizing the efficiency and versatility of the vector-
based gene silencing approach. We consider our current
work as an important step forward in the vector-based
siRNA technology development. Specifically, the vectors
containing multiple siRNA expression cassettes have two
important applications: First these vectors can produce
different siRNA to knock down the expression of different
genes; secondly, they can be used to maximize the silenc-
ing of a singe gene. In Fig. 4a, we use p6-siRNA as an
example to explain the two major applications. 6 different
DNA inserts encoding effective siRNA targeting 6 different
genes (Genes A, B, C, D, E and F) may be cloned into p6-
siRNA. Once these vectors are delivered into mammalian
cells by transient transfection or by viral technology, one
single vector would produce 6 different siRNA to induce
degradation of 6 different transcripts (Genes A, B, C, D, E
and F). This feature is very attractive because many studies
such as cell signaling pathway analysis necessitate the
silencing of multiple genes.
Moreover, as shown in Fig. 4b, p6-siRNA may be used to
maximize the down-regulation of a single gene expres-
sion. This can be achieved in two ways. First, DNA inserts
containing the same siRNA are cloned into all six siRNA
expression cassettes in p6-siRNA vector (left panel, Fig.
4b). Consequently, one such vector would produce six
times more siRNA than a vector containing only one
siRNA expression cassette, resulting in a dramatic increase
in efficiency of gene silencing. Alternatively, 6 different
siRNA inserts are cloned into p6-siRNA to produce 6 dis-
tinct siRNA to target different regions of the same gene to
maximize the down-regulation of its expression (Gene X)
(right panel, Fig. 4b).
As shown in Fig. 1b, we developed six vectors with differ-
ent number of siRNA expression cassettes. We would like
to point out that the use of an appropriate vector is very
critical for achieving the maximal efficiency of gene silenc-
ing. For instance, if one plans to use 4 different siRNA
sequences, it is critical to use p4-siRNA rather than p5-
Diagram depicting the ability of vectors containing multiple  siRNA expression cassettes to simultaneously suppress the  expression of multiple genes or to maximize the silencing of  a singe gene Figure 4
Diagram depicting the ability of vectors containing 
multiple siRNA expression cassettes to simultane-
ously suppress the expression of multiple genes or to 
maximize the silencing of a singe gene. a) p6-siRNA 
can express 6 distinct siRNA to suppress the expression of 
six different genes (Genes A, B, C, D, E and F). b) p6-siRNA 
can be used to maximize the efficiency of gene silencing 
(Gene X) by expressing 6 copies of siRNA targeting the same 
region of Gene X or by expressing 6 distinct siRNA targeting 
different regions of Gene X.
p2-siRNA is able to produce two different siRNAs targeting  different regions of TRAF6 mRNA or two copies of the same  siRNA to increase the efficiency of gene silencing Figure 3
p2-siRNA is able to produce two different siRNAs 
targeting different regions of TRAF6 mRNA or two 
copies of the same siRNA to increase the efficiency of 
gene silencing. a) Construction and schematic diagram of 
Vec2, Vec6, Vec26 and Vec66. In addition, schematic location 
of sequence Si6A and Si6 are also depicted. UTR: untrans-
lated region. Sequence of Si6 and Si6A are shown in addi-
tional files (see Additional file 2). b) Western analysis 
showing that Vec66 exerts higher inhibitory effect on TRAF6 
expression than Vec6. C: uninfected BMMs control. Actin 
was probed as loading control. The expression levels of 
TRAF proteins were normalized to that of actin. These 
Western blot assays were independently repeated three 
times and a representative data is shown. c) Western analysis 
showing that Vec26 exerts higher inhibitory effect on TRAF6 
expression than Vec2 or Vec6. C: uninfected BMMs control. 
Vec2C: control containing the scrambled Si6A sequence. 
Vec6C: control containing the scrambled Si6 sequence.BMC Biotechnology 2006, 6:50 http://www.biomedcentral.com/1472-6750/6/50
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siRNA or p6-siRNA despite that both p5-siRNA and p6-
siRNA can accommodate 4 different siRNA inserts. If p6-
siRNA is used, 4 siRNA cassettes contain DNA inserts and
other two remain empty. Once the p6-siRNA is transfected
into cells, U6 promoters in all 6 siRNA expression cas-
settes will recruit Pol III no matter whether they contain
an DNA insert or not. As such, the two empty siRNA cas-
settes would negatively affect the efficiency of the 4 insert-
containing cassettes since the two U6 promoters in the
empty cassettes would compete with the four U6 promot-
ers in the insert-containing cassettes for Pol III. Thus, in
this case, in order to achieve the maximal efficiency of
gene silencing, p4-siRNA vector should be used.
The vectors shown in Fig. 1b represent only prototypes of
this series of siRNA expression vectors. Using a similar
cloning strategy, we may develop additional vectors to
improve the power and efficiency of the siRNA vectors
containing multiple siRNA expression cassettes. First,
since the vectors shown in Fig. 1b utilizes mouse U6 pro-
moter to produce siRNA, these vectors may not be as effi-
cient in human cells as in mouse cells. Thus, we may
develop similar vectors for silencing multiple genes in
human cells by using human U6 promoter. Secondly, we
may also develop vectors in which both mouse U6 pro-
moter and mouse H1 promoter are used to produce siRNA
in the same vector. Inclusion of both types of Pol III pro-
moters may increase the efficiency of these vectors. For
example, when p6-siRNA shown in Fig. 1b is transfected
into cells, 6 U6 promoters will have to compete for the
transcription factors available in the cells. In contrast, if
p6-siRNA vector contains 3 U6 promoters and 3 H1 pro-
moters, only 3 U6 promoters will have to share the same
amount of the transcription factors for the U6 promoter.
The other 3 H1 promoters in the vector will recruit the
transcription factors for the H1 promoters. As a result,
each U6 promoter should have access to more transcrip-
tion factors (twice more) and this may lead to production
of more siRNA.
Conclusion
Using an efficient cloning strategy, we have constructed
siRNA expression vectors containing multiple (up to 6)
siRNA expression cassettes. These vectors can be used to
simultaneously knock down the expression of different
genes or to maximize the gene silencing of a single gene.
Thus, these vectors are more powerful and versatile than
the siRNA expression vectors currently available. Moreo-
ver, using the same cloning strategy, we are capable of
constructing additional vectors containing multiple
siRNA expression cassettes which may further improve the
efficiency of gene silencing in cells of interest.
Methods
Construction of siRNA expression vectors
The standard molecular cloning methods were used to
construct the vectors containing multiple siRNA expres-
sion cassettes with the oligonucleotides shown in Fig. 1a
and additional files (see Additional file 1). A mouse U6
promoter (mU6) (from -315 to +1 relative to the tran-
scription start site) was amplified by PCR using mouse
genomic DNA using the following pair of primers: the for-
ward primer 5'-taaactagtgacgccgccatctctaggcccgcg-3' and
the reverse primer 5'-tatctcgagtctccaagggatatttatagtctc-
caaaac-3. The forward primer contains a Spe I site at its 5'
end (underlined) while the reverse primer has a Xho I site
at its 5' end (underlined). The PCR product was cloned
into SK+ between Spe I and Xho I to give rise to SK-mU6.
The PCR product was confirmed by sequencing.
Culturing and infection of BMMs
Bone marrow cells were isolated from long bones of 4–8
week old mice (Harlan Industries, Indianapolis, IN) as
described [13]. BMMs were prepared by culturing isolated
bone marrow cells in α-minimal essential medium con-
taining 10% heat-inactivated FBS in the presence of 0.1
volume of culture supernatant of monocyte/macrophage
colony stimulating factor (M-CSF)-producing cells for 2
days as previously described [14].
Retrovirus was prepared using Plat-E packaging cells [15].
Plat-E cells were cultured in Dulbecco's modified eagle
medium with 10% heat-inactivated FBS as described pre-
viously [15] and transiently transfected with the viral vec-
tors containing multiple siRNA expression cassettes using
Lipofectamine Plus (Invitrogen, Carlsbad, CA) as
described previously [11]. Virus supernatant was collected
at 48, 72 and 96 hours after transfection. BMMs were then
infected with virus for 24 hours in the presence of 0.1 vol-
ume of culture supernatant of M-CSF-producing cells and
8 μg/ml polybrene. Cells were further cultured in the pres-
ence of M-CSF and 2 μg/ml puromycin for selection and
expansion of transduced cells. Selected cells were subse-
quently used for Western analysis.
Western analysis
BMMs infected with retrovirus or control BMMs (unin-
fected) were cultured in α-MEM in the presence of M-CSF
(22 ng/ml). Cells were washed twice with ice-cold phos-
phate-buffered saline (PBS) and then lysed in buffer con-
taining 20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 mM
NaF, and 1× protease inhibitor cocktail 1 (Sigma, P-2850)
and 1× protease inhibitor cocktail 2 (Sigma, P-5726).
Lysates were then subjected to Western analysis as
described in our previous study [11]. Antibodies against
TRAF1 (sc-874), TRAF2 (sc-876) and TRAF6 (sc-8409)Publish with BioMed Central    and   every 
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were purchased from Santa Cruz, Inc (Santa Cruz, CA).
Membranes were washed extensively and enhanced
chemiluminescence detection assay was performed using
SuperSignal West Dura kit from Pierce (Rockford, IL).
Quantification of the blots was performed using
FlourChem v2.0 from Alpha Innotech Corporation (San
Leandro, CA).
Abbreviations
RNAi, RNA interference; dsRNA, double-stranded RNA;
siRNA, small interfering RNA; Pol III, RNA polymerase III;
mRNA, messenger RNA; SK+, pBluescript II SK+; MCS,
multiple cloning sites; mU6, mouse U6 promoter; BMMs,
bone marrow macrophages; M-CSF, monocyte/macro-
phage colony stimulating factor; PBS, phosphate-buffered
saline.
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Additional File 1
Construction of p3-siRNA, p4-siRNA, p5-siRNA and p6-siRNA. The data 
provided describe the detailed procedures for constructing p3-siRNA, p4-
siRNA, p5-siRNA and p6-siRNA.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-6-50-S1.pdf]
Additional File 2
Sequence and structure of Si1, Si2, Si6 and Si6A. The table provided 
describes the detailed information on sequence and structure of Si1, Si2, 
Si6 and Si6A.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-6-50-S2.pdf]